Nathaniel R. Smilowitz

Nathaniel R. Smilowitz

Auto-generated profile, based on publicly available information

Nathaniel R. Smilowitz

Division of Cardiology, Department of Medicine, NYU Grossman School of Medicine, New York, New York, USA; Department of Medicine, Cardiology Section, VA New York Harbor Healthcare System, New York, New York, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in European Heart Journal
Verified
Journal Article
Open access
PDF file
NSNathaniel R Smilowitz
Nathaniel R Smilowitz
DKDennis Kunichoff
Dennis Kunichoff
MGMichael Garshick
Michael Garshick
BSBinita Shah
Binita Shah
MPMichael Pillinger
Michael Pillinger
JBJeffrey S Berger
Jeffrey S Berger
Background: A systemic inflammatory response is observed in coronavirus disease 2019 (COVID-19). Elevated serum levels of C-reactive protein (CRP), a marker of systemic inflammation, are associated with severe disease in bacterial or viral infections. We aimed to explore associations between CRP concentration at initial hospital presentation and clinical outcomes in patients with COVID-19. Methods and results: Consecutive adults aged ≥18 years with COVID-19 admitted to a large New York healthcare system between 1 March and 8 April 2020 were identified. Patients with measurement of CRP were included. Venous thrombo-embolism (VTE), acute kidney injury (AKI), critical illness, and in-hospital mortality were determined for all patients. Among 2782 patients hospitalized with COVID-19, 2601 (93.5%) had a CRP measurement [median 108 mg/L, interquartile range (IQR) 53–169]. CRP concentrations above the median value were associated with VTE [8.3% vs. 3.4%; adjusted odds ratio (aOR) 2.33, 95% confidence interval (CI) 1.61–3.36], AKI (43.0% vs. 28.4%; aOR 2.11, 95% CI 1.76–2.52), critical illness (47.6% vs. 25.9%; aOR 2.83, 95% CI 2.37–3.37), and mortality (32.2% vs. 17.8%; aOR 2.59, 95% CI 2.11–3.18), compared with CRP below the median. A dose response was observed between CRP concentration and adverse outcomes. While the associations between CRP and adverse outcomes were consistent among patients with low and high D-dimer levels, patients with high D-dimer and high CRP have the greatest risk of adverse outcomes. Conclusions: Systemic inflammation, as measured by CRP, is strongly associated with VTE, AKI, critical illness, and mortality in COVID-19. CRP-based approaches to risk stratification and treatment should be tested.

1 November 2019 in Cardiology in Review
Verified
Journal Article
Closed access
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
GRGabriel Bs Redel-Traub
Gabriel Bs Redel-Traub
AHAnais Hausvater
Anais Hausvater
AAAndrew Armanious
Andrew Armanious
JNJoseph Nicholson
Joseph Nicholson
JBJeffrey S. Berger
Jeffrey S. Berger
Myocardial injury after noncardiac surgery (MINS) is a common postoperative complication associated with adverse cardiovascular outcomes. The purpose of this systematic review was to determine the incidence, clinical features, pathogenesis, management, and outcomes of MINS. We searched PubMed, Embase, Central and Web of Science databases for studies reporting the incidence, clinical features, and prognosis of MINS. Data analysis was performed with a mixed-methods approach, with quantitative analysis of meta-analytic methods for incidence, management, and outcomes, and a qualitative synthesis of the literature to determine associated preoperative factors and MINS pathogenesis. A total of 195 studies met study inclusion criteria. Among 169 studies reporting outcomes of 530,867 surgeries, the pooled incidence of MINS was 17.9% [95% confidence interval (CI), 16.2–19.6%]. Patients with MINS were older, more frequently men, and more likely to have cardiovascular risk factors and known coronary artery disease. Postoperative mortality was higher among patients with MINS than those without MINS, both in-hospital (8.1%, 95% CI, 4.4–12.7% vs 0.4%, 95% CI, 0.2–0.7%; relative risk 8.3, 95% CI, 4.2–16.6, P < 0.001) and at 1-year after surgery (20.6%, 95% CI, 15.9–25.7% vs 5.1%, 95% CI, 3.2–7.4%; relative risk 4.1, 95% CI, 3.0–5.6, P < 0.001). Few studies reported mechanisms of MINS or the medical treatment provided. In conclusion, MINS occurs frequently in clinical practice, is most common in patients with cardiovascular disease and its risk factors, and is associated with increased short- and long-term mortality. Additional investigation is needed to define strategies to prevent MINS and treat patients with this diagnosis.

1 June 2023 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
OTOlga Toleva
Olga Toleva
ACAlaide Chieffo
Alaide Chieffo
DPDivaka Perera
Divaka Perera
CBColin Berry
Colin Berry
Coronary microvascular disease (CMD) causes myocardial ischemia in a variety of clinical scenarios. Clinical practice guidelines support routine testing for CMD in patients with ischemia with nonobstructive coronary artery disease. Invasive testing to identify CMD requires Doppler or thermodilution measures of flow to determine the coronary flow reserve and measures of microvascular resistance. Acetylcholine coronary reactivity testing identifies concomitant endothelial dysfunction, microvascular spasm, or epicardial coronary spasm. Comprehensive testing may improve symptoms, quality of life, and patient satisfaction by establishing a diagnosis and guiding-targeted medical therapy and lifestyle measures. Beyond ischemia with nonobstructive coronary artery disease, testing for CMD may play a role in patients with acute myocardial infarction, angina following coronary revascularization, heart failure with preserved ejection fraction, Takotsubo syndrome, and after heart transplantation. Additional education and provider awareness of CMD and its role in cardiovascular disease is needed to improve patient-centered outcomes of ischemic heart disease.

18 July 2018 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
DMDivyanshu Mohananey
Divyanshu Mohananey
LRLouai Razzouk
Louai Razzouk
GWGiora Weisz
Giora Weisz
JSJames N. Slater
James N. Slater

1 May 2019 in The American Journal of Cardiology
Verified
Journal Article
Closed access
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
AAAndrew Armanious
Andrew Armanious
SBSripal Bangalore
Sripal Bangalore
HRHarish Ramakrishna
Harish Ramakrishna
JBJeffrey S. Berger
Jeffrey S. Berger

1 January 2021 in American Heart Journal
Verified
Journal Article
Closed access
NSNathaniel R. Smilowitz
Nathaniel R. Smilowitz
VSVarun Subashchandran
Varun Subashchandran
EYEugene Yuriditsky
Eugene Yuriditsky
JHJames M. Horowitz
James M. Horowitz
HRHarmony R. Reynolds
Harmony R. Reynolds
JBJeffrey S. Berger
Jeffrey S. Berger